STOCK TITAN
  1. Home
  2. Sec-filings
  3. CMMB
  4. [Form 3] Chemomab Therapeutics Ltd. Initial Statement of Beneficial Ownership

Chemomab (CMMB) director Claude Nicaise lists six vested option grants

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
3

Rhea-AI Filing Summary

Chemomab Therapeutics Ltd. director Claude Nicaise reported his initial holdings of stock options to buy the company’s American Depositary Shares. The filing lists six option awards with exercise prices ranging from $2.14 to $109.04 per share and expiration dates between 2031 and 2036. Footnotes state that options granted on April 19, 2021, March 7, 2022, March 21, 2023, March 18, 2024 and March 16, 2025 are fully vested and exercisable as of the report date. The Form 3 records ownership only and does not show any recent purchases or sales.

Positive

  • None.

Negative

  • None.
Insider Nicaise Claude
Role Director
Type Security Shares Price Value
holding Stock option (right to buy American Depositary Shares) -- -- --
holding Stock option (right to buy American Depositary Shares) -- -- --
holding Stock option (right to buy American Depositary Shares) -- -- --
holding Stock option (right to buy American Depositary Shares) -- -- --
holding Stock option (right to buy American Depositary Shares) -- -- --
holding Stock option (right to buy American Depositary Shares) -- -- --
Holdings After Transaction: Stock option (right to buy American Depositary Shares) — 2,971 shares (Direct)
Footnotes (1)
  1. The options reported in this row were granted to the Reporting Person by the Issuer on April 19, 2021, and are fully vested and exercisable as of the date of this report. The options reported in this row were granted to the Reporting Person by the Issuer on March 7, 2022, and are fully vested and exercisable as of the date of this report. The options reported in this row were granted to the Reporting Person by the Issuer on March 21, 2023, and are fully vested and exercisable as of the date of this report. The options reported in this row were granted to the Reporting Person by the Issuer on March 18, 2024, and are fully vested and exercisable as of the date of this report. The options reported in this row were granted to the Reporting Person by the Issuer on March 16, 2025, and are fully vested and exercisable as of the date of this report.
Option grant 1 exercise price <money>$109.04</money> per share Stock option on 2,971 underlying American Depositary Shares, expiration <date>April 19, 2031</date>
Option grant 2 exercise price <money>$14.12</money> per share Stock option on 1,705 underlying American Depositary Shares, expiration <date>March 7, 2032</date>
Option grant 3 exercise price <money>$6.48</money> per share Stock option on 1,714 underlying American Depositary Shares, expiration <date>March 21, 2033</date>
Option grant 4 exercise price <money>$2.96</money> per share Stock option on 2,520 underlying American Depositary Shares, expiration <date>March 18, 2034</date>
Option grant 5 exercise price <money>$6.16</money> per share Stock option on 3,821 underlying American Depositary Shares, expiration <date>March 16, 2035</date>
Option grant 6 exercise price <money>$2.14</money> per share Stock option on 5,172 underlying American Depositary Shares, expiration <date>March 16, 2036</date>
Stock option (right to buy American Depositary Shares) financial
"security_title: Stock option (right to buy American Depositary Shares)"
American Depositary Shares financial
"underlying_security_title: American Depositary Shares"
American depositary shares (ADSs) are a way for investors in the United States to buy shares of foreign companies without dealing with international markets directly. They represent ownership in a foreign company's stock and are traded on U.S. stock exchanges, making it easier for American investors to buy, sell, and own parts of companies from around the world.
exercise price financial
"conversion_or_exercise_price: 109.0400"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
expiration date financial
"expiration_date: 2031-04-19T00:00:00.000Z"
The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.
fully vested and exercisable financial
"are fully vested and exercisable as of the date of this report"
Understanding Insider Trading Forms →
SEC Form 3
FORM 3UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0104
Estimated average burden
hours per response:0.5
1. Name and Address of Reporting Person*
Nicaise Claude
(Last)(First)(Middle)
C/O CHEMOMAB THERAPEUTICS LTD.
10 HABARZEL STBUILDING C, 10TH FLOOR
(Street)
TEL AVIV6158101
(City)(State)(Zip)
ISRAEL
(Country)		2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026		3. Issuer Name and Ticker or Trading Symbol
Chemomab Therapeutics Ltd. [ CMMB ]
3a. Foreign Trading Symbol
5. If Amendment, Date of Original Filed (Month/Day/Year)
4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
Table II - Derivative Securities Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year)3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock option (right to buy American Depositary Shares) (1)04/19/2031American Depositary Shares2,971$109.04D
Stock option (right to buy American Depositary Shares) (2)03/07/2032American Depositary Shares1,705$14.12D
Stock option (right to buy American Depositary Shares) (3)03/21/2033American Depositary Shares1,714$6.48D
Stock option (right to buy American Depositary Shares) (4)03/18/2034American Depositary Shares2,520$2.96D
Stock option (right to buy American Depositary Shares) (5)03/16/2035American Depositary Shares3,821$6.16D
Stock option (right to buy American Depositary Shares)03/16/202703/16/2036American Depositary Shares5,172$2.14D
Explanation of Responses:
1. The options reported in this row were granted to the Reporting Person by the Issuer on April 19, 2021, and are fully vested and exercisable as of the date of this report.
2. The options reported in this row were granted to the Reporting Person by the Issuer on March 7, 2022, and are fully vested and exercisable as of the date of this report.
3. The options reported in this row were granted to the Reporting Person by the Issuer on March 21, 2023, and are fully vested and exercisable as of the date of this report.
4. The options reported in this row were granted to the Reporting Person by the Issuer on March 18, 2024, and are fully vested and exercisable as of the date of this report.
5. The options reported in this row were granted to the Reporting Person by the Issuer on March 16, 2025, and are fully vested and exercisable as of the date of this report.
Remarks:
This Form 3 has been filed after March 18, 2026 but prior to April 20, 2026 in reliance on the temporary relief made available to the directors and officers of certain foreign private issuers by the Staff of the Securities and Exchange Commission in its no-action letter dated March 13, 2026.
/s/ Claude Nicaise03/27/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What does Chemomab (CMMB) director Claude Nicaise report on this Form 3?

Claude Nicaise reports his initial beneficial ownership in Chemomab through several stock options to buy American Depositary Shares. The filing lists six option awards with specific exercise prices and expiration dates, establishing his starting equity position as a company director.

How many Chemomab (CMMB) option grants are disclosed for Claude Nicaise?

The Form 3 discloses six separate stock option grants, each covering American Depositary Shares of Chemomab. These options differ by exercise price and expiration date, together outlining the structure and timing of Nicaise’s potential future share ownership in the company.

What are the exercise price ranges of Claude Nicaise’s Chemomab (CMMB) options?

Nicaise’s reported Chemomab options have exercise prices ranging from $2.14 to $109.04 per American Depositary Share. This spread reflects option grants made over multiple years at different market levels, providing varied potential cost bases for future share acquisition.

When do Claude Nicaise’s Chemomab (CMMB) options expire?

The disclosed Chemomab stock options expire between April 19, 2031 and March 16, 2036, depending on the specific grant. These multi‑year expiration dates give Nicaise a long window to decide if and when to exercise his rights to buy American Depositary Shares.

Are Claude Nicaise’s Chemomab (CMMB) options vested and exercisable?

Footnotes explain that options granted on April 19, 2021, March 7, 2022, March 21, 2023, March 18, 2024 and March 16, 2025 are fully vested and exercisable as of the report date. This means Nicaise can choose to exercise those grants at their stated exercise prices.

Does this Chemomab (CMMB) Form 3 show insider buying or selling?

No, the Form 3 functions as an initial ownership report and does not show open‑market buying or selling. It lists existing stock option holdings, including exercise prices and expirations, but transaction fields indicate no purchases, sales, or option exercises in this particular filing.